| Industry | 制造业 | ||||||||||||||||||||||||
| Company Introduction | 汇宇制药成立于2010年，是一家研发驱动的综合制药企业，主要从事抗肿瘤和注射剂药物的研发、生产和销售。公司总部和生产基地位于内江市国家级经济技术开发区，研发中心坐落于成都市天府国际生物城，并且在美国、英国和爱尔兰等地设有子公司。 公司的研发团队以经验丰富的海归博士为核心，研发人员637人，占公司总人数的47.19%，在化学原料药、化学普通注射剂和复杂注射剂等方面有丰富的研发经验，同时积极推进抗肿瘤领域的小分子创新药和生物大分子创新药的研发，公司100+在研项目，包含13个一类创新药及3个改良新药项目，管线以肿瘤及相关领域为主，同时逐步覆盖其它领域。 在海外，汇宇制药2014年首次通过英国GMP认证，2015年7月全资子公司英国海玥药业通过欧盟药品放行资质认证，同年自主品牌抗肿瘤注射剂在欧盟实现规模化销售。公司自有或授权合作方持有海外批件超过300件，在近100个国家签订了合作协议，覆盖6大洲。目前汇宇在英国有16个一线抗肿瘤注射剂及2个其他领域制剂获得上市批准，并在海外超过1300家医疗机构上市销售。公司在2022年下半年接受并顺利完成美国FDA的现场认证，使得公司生产质量管理体系已满足中国、欧盟和美国等主流国际化标准的要求。 在国内，2017年注射用培美曲塞二钠，在同品种中首家通过一致性评价，次年中标国家集采，在国内开始大规模销售，覆盖了超过2000家等级医院。2021年10月26号正式登陆科创板，成为一家国际化视野的创新药企。目前公司有注射用培美曲塞二钠、多西他赛注射液、注射用阿扎胞苷、紫杉醇注射液、奥沙利铂注射液、注射用盐酸苯达莫司汀、伊立替康注射液、注射用硼替佐米、盐酸帕洛诺司琼注射液、普乐沙福注射液、注射用盐酸表柔比星等21个药品获批上市，均视同通过注射剂一致性评价，且其中多个品种为首家或前三家过评。 | ||||||||||||||||||||||||
| Main Business | 从事肿瘤治疗领域药物和复杂注射剂药物的研发、生产和国内外销售。 | ||||||||||||||||||||||||
| Legal Representative | 丁兆 | ||||||||||||||||||||||||
| Top Executives |
|
||||||||||||||||||||||||
| Top 5 Shareholder |
|
||||||||||||||||||||||||
| Company Secretary | 马莉娜 | ||||||||||||||||||||||||
| Solicitors | 上海东方华银律师事务所 | ||||||||||||||||||||||||
| Auditors | 天健会计师事务所（特殊普通合伙） | ||||||||||||||||||||||||
| Tel No | 0832-8808000 | ||||||||||||||||||||||||
| Fax No | 0832-8808111 | ||||||||||||||||||||||||
| Website | www.huiyupharma.com | ||||||||||||||||||||||||
| ir@huiyupharma.com | |||||||||||||||||||||||||
| Company Address |
|
||||||||||||||||||||||||
| Listing Date | 26/10/2021 | ||||||||||||||||||||||||
| Shares Capital |
|
||||||||||||||||||||||||
| EPS(RMB)* | ¥ 0.330 | ||||||||||||||||||||||||
| DPS(RMB)* | ¥ 0.213 | ||||||||||||||||||||||||
| NBV Per Share(RMB)* | ¥ 8.901 | ||||||||||||||||||||||||
| Market Capitalization(RMB) | 4.108B |
 |
Only Chinese content is avaliable |
|
N
/
N
: Eligible Stock for SH-HK Northbound trade (For all investors/ For institutional professional investors only)
N
: Eligible Stock for SH-HK Ex-Northbound trade (sell only)
|
|
|
N
/
N
: Eligible Stock for SZ-HK Northbound trade (For all investors/ For institutional professional investors only)
N
: Eligible Stock for SZ-HK Ex-Northbound trade (sell only)
|
|
| * | Unadjusted Data |
| Information provided by: etnet | ||
| Terms and Conditions | ||
| Risk Disclosure: |
| The prices of securities may fluctuate, sometimes dramatically. The price of a security may move up or down, and may become valueless. It is as likely that losses will be incurred rather than profit made as a result of buying and selling securities. The information is for reference only, it does not constitute any offer, solicitation, recommendation, comment or any guarantee to the purchase or sale of any investment product or service. Customers should not make any investment decisions based on this information alone. |
| Disclaimer: |
| This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources, Nanyang Commercial Bank Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information. |